MASTER AGREEMENTMaster Agreement • June 14th, 2012 • Advaxis, Inc. • Pharmaceutical preparations • Pennsylvania
This Master Agreement (“Agreement”) is made as of June 12, 2009 (the “Effective Date”) by and between Advaxis, Inc., with a place of business at 675 US Highway 1, Suite 117, North Brunswick, NJ 08902 (hereinafter “Sponsor” or “Advaxis”), and Numoda Corporation having its principal place of business at 601 Walnut Street, Philadelphia, PA 19106 USA (hereinafter “Numoda”). When signed by both parties, this Agreement will set forth the terms and conditions under which Numoda agrees to provide certain services to Advaxis as set forth herein.
Third Amendment to the Amended and Restated Patent License AgreementLicense Agreement • June 14th, 2012 • Advaxis, Inc. • Pharmaceutical preparations
This Third Amendment (the “Third Amendment”) is made and entered into as of December 12, 2011 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania (hereinafter referred to as “Penn”) and Advaxis, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as “Company”) having a place of business at 305 College Road East, Princeton, NJ 08540.
FORM OF PROJECT AGREEMENT FOR PROTOCOL #: ___________Advaxis, Inc. • June 14th, 2012 • Pharmaceutical preparations
Pursuant to the Master Agreement entered into by Advaxis, Inc. (“ADVAXIS”) and Numoda Corporation (“Numoda”) on June 19, 2009 (“MA”), this Project Agreement (PA) and attachments, including:
CLINICAL TRIAL SERVICES AGREEMENTClinical Trial Services Agreement • June 14th, 2012 • Advaxis, Inc. • Pharmaceutical preparations • Pennsylvania
This Clinical Trial Services Agreement (“Agreement”) is between Advaxis, Inc. (“Sponsor”), a for-profit corporation organized under the laws of Delaware, USA and holder of IND Number 13712, and the Gynecologic Oncology Group (“GOG”), a not-for-profit corporation organized under the laws of the District of Columbia, to conduct the Clinical Trial according to the Protocol attached as Exhibit A and incorporated by reference in this Agreement. The Principal Investigator for the GOG shall be Philip J. DiSaia, M.D. The Clinical Trial will be directed by Warner K. Huh, M.D. (“Study Chair”), according to the Protocol.
First Amendment to the Amended and Restated Patent License AgreementPatent License Agreement • June 14th, 2012 • Advaxis, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT (the “Amendment”) is made and entered into as of March 26, 2007 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania (hereinafter referred to as “PENN”) and Advaxis, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as “COMPANY”) having a place of business at Technology Centre of New Jersey, Suite 117, 675 U.S. Route 1, North Brunswick, NJ 08902.
